M.D., Ph.D., President and CEO, Asuragen
Dr. McManus joined in August 2014 bringing more than 20 years of clinical diagnostic leadership experience. Matt was most recently CEO and President of PrimeraDx, Inc., a molecular diagnostics company acquired by Qiagen. He has held leadership positions in a number of other companies, including as Head of Cleveland Clinic Laboratories, COO of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic, and a variety of positions at Novartis, McKinsey & Co., and Procter & Gamble. Dr. McManus received his M.D. and Ph.D. from the University of Pennsylvania, M.B.A from Boston College and B.A. from the College of the Holy Cross.
Challenges to Creating Diagnostic Tests Across the Entire Genome
Short structural variants (SSVs) and repetitive sequences are as important as “standard” genomic sequences, but have been exceptionally difficult to detect. Asuragen has developed novel technologies addressing not only the “known genome,” but now also the previously dark matter of SSVs/repeats, with a portfolio integrating both halves of the genome.